| GTO ID | GTC2662 |
| Trial ID |
NCT04847050
|
| Disease |
Lymphoma
|
Multiple Myeloma
|
Leukemia
|
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster Doses of Vaccine |
| Year | 2021 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 10000115|000115-C |